01 febrero 2015

AMERICAN HEART JOURNAL. Improving the process of informed consent for percutaneous coronary intervention: Patient Outcomes from the Patient Risk Information Services Manager (ePRISM) study

John A. Spertus, MD MPH, Richard Bach, MD, Charles Bethea, MD, Adnan Chhatriwalla, MD, Jeptha P. Curtis, MD, Elizabeth Gialde, RN, Mayra Guerrero, MD, Kensey Gosch, MS, Philip G. Jones, MS, Aaron Kugelmass, MD, Bradley M. Leonard, MD, Edward J. McNulty, MD, Marc Shelton, MD, Henry H. Ting, MD MBA, Carole Decker, RN PhD

Background: While the process of informed consent is designed to transfer knowledge of the risks and benefits of treatment and to engage patients in shared medical decision-making, this is poorly done in routine clinical care. We assessed the impact of a novel informed consent form for percutaneous coronary intervention (PCI) that is more simply written, includes images of the procedure, and embeds individualized estimates of outcomes on multiple domains of successful informed consent and shared decision-making.

01 febrero 2015

AMERICAN HEART JOURNAL. Predictors and impact of target vessel revascularization after stent implantation for acute ST-segment elevation myocardial infarction: Lessons from HORIZONS-AMI

Sorin J. Brener, MD, Konstanze Ertelt, MD, Roxana Mehran, MD, Philippe Genereux, MD, Ke Xu, MS, Bernhard Witzenbichler, MD, Bruce R. Brodie, MD, Giulio Guagliumi, MD, Gregg W. Stone, MD

Background: Target vessel revascularization (TVR) may compromise the benefits of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (STEMI) We set out to identify the predictors and examine the impact of TVR after STEMI in patients receiving a coronary stent.

01 febrero 2015

AMERICAN HEART JOURNAL. Suboptimal stent deployment is associated with subacute stent thrombosis: Optical coherence tomography insights from a multicenter matched study. From the CLI Foundation investigators: the CLI-THRO study

Francesco Prati, MD, Takahide Kodama, MD, Enrico Romagnoli, MD, Laura Gatto, MD, Luca Di Vito, MD, Vito Ramazzotti, MD, Alberto Chisari, MD, Valeria Marco, RN, Alberto Cremonesi, MD, Guido Parodi, MD, Mario Albertucci, MD, Fernando Alfonso, MD

Background: Acute or subacute stent thrombosis (ST) is a well-described complication usually causing acute coronary syndromes and, in the worst case scenario, sudden cardiac death. In this study, we aimed at exploring the potential role of optical coherence tomography (OCT) in the understanding of the mechanism of ST.

13 marzo 2015

THE LANCET. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials

Tullio Palmerini, MD, Umberto Benedetto, PhD, Letizia Bacchi-Reggiani, MStat, Diego Della Riva, MD, Giuseppe Biondi-Zoccai, MD, Fausto Feres, MD, Alexandre Abizaid, MD, Myeong-Ki Hong, MD, Byeong-Keuk Kim, MD, Yangsoo Jang, MD, Hyo-Soo Kim, MD, Kyung Woo Park, MD, Philippe Genereux, MD, Deepak L Bhatt, MD, Carlotta Orlandi, MD, Stefano De Servi, MD, Mario Petrou, PhD, Claudio Rapezzi, MD, Dr Gregg W Stone, MD

Background: Despite recent studies, the optimum duration of dual antiplatelet therapy (DAPT) after coronary drug-eluting stent placement remains uncertain. We performed a meta-analysis with several analytical approaches to investigate mortality and other clinical outcomes with different DAPT strategies.

01 diciembre 2014

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-eluting stents and bare metal stents in patients with acute coronary syndrome

Alfazir Omar MBChB, Rebecca Torguson MPH, Hironori Kitabata MD, PhD, Lakshmana K. Pendyala MD, Joshua P. Loh MBBS, Marco A. Magalhaes MD, Lowell F. Satler MD, William O. Suddath MD, Augusto D. Pichard MD andRon Waksman MD*

Objectives: This study aimed to investigate the long-term safety and efficacy of everolimus-eluting stents (EES) compared with other limus-eluting stents and bare metal stents (BMS) in ACS patients.

01 diciembre 2014

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Baseline and 9 months IVUS analysis of the bifurcation-dedicated biolimus A9-eluting Axxess stent system: The DIVERGE IVUS substudy

Ian Buysschaert MD PhD1, Elias Sanidas MD PhD1, Takao Hasegawa MD2, Bon-Kwon Koo MD PhD2, Yasuhiro Honda MD2, Peter J. Fitzgerald MD PhD2 andStefan Verheye MD PhD1,*

Background: Percutaneous treatment of complex coronary bifurcation lesions remains challenging, even in the drug-eluting stent era. We sought to evaluate the baseline and 9 months intravascular ultrasound (IVUS) analysis of the Axxess™ stent, a self-expanding, Biolimus A9™-eluting, and dedicated bifurcation stent.

01 diciembre 2014

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Incidence of adverse cardiac events 5 years after polymer-free sirolimus eluting stent implantation: Results from the prospective Bad Berka Yukon Choice™ registry

Marc-Alexander Ohlow MD1,*, Hubertus von Korn MD2, Oliver Gunkel MD3, Ahmed Farah MD1, Joerg T. Fuhrmann MD1 andBernward Lauer PhD1

Objectives: Drug-eluting stents (DES) constitute a major achievement in preventing re-stenosis, concerns remain regarding the increased inflammatory responses associated with the polymers used. This analysis focuses on outcomes in patients receiving the polymer-free sirolimus-eluting stent system YUKON-Choice (Yukon-DES, Translumina, Germany).

01 diciembre 2014

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Inhibition of neo-intimal hyperplasia in porcine coronary arteries utilizing a novel paclitaxel-coated scoring balloon catheter

Bodo Cremers MD1, Stephanie Schmitmeier PhD2, Yvonne P. Clever MD1, Gary Gershony MD3, Ulrich Speck PhD4 andBruno Scheller MD1,*

Objective: Scoring balloons are particularly useful in the acute treatment of fibro-calcific, bifurcation and in-stent restenosis lesions but have not been shown to affect the restenosis rate. Conventional balloons coated with paclitaxel have recently been shown to reduce restenosis rates in certain lesion subsets, but are associated with suboptimal acute results. A novel paclitaxel-coated scoring balloon was developed to overcome these limitations.

01 diciembre 2014

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. First-in-Man Study of the Low-Dose Paclitaxel Using the COBRA-P Drug-Eluting Coronary Stent System With a Novel Biodegradable Coating in De Novo Coronary Lesions

Daisaku Nakatani MD, PhD1, Katsuhisa Waseda MD, PhD1, Junya Ako MD, PhD1, Carlos Calderas MD2, Jose A. Condado MD3, Jose F. Condado MD3, Yasuhiro Honda MD1 andPeter J. Fitzgerald MD, PhD1,*

Objective: The aim of this first-in-man trial was to evaluate vessel response of two doses of the balloon expandable Cobra-P drug-eluting coronary stent (DES).

01 diciembre 2014

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Amplatzer left atrial appendage occlusion through a patent foramen ovale

Dezsoe Koermendy MD†, Fabian Nietlispach MD†, Samera Shakir MD, Steffen Gloekler MD, Peter Wenaweser MD, Stephan Windecker MD, Ahmed A. Khattab MD andBernhard Meier MD*

Objectives: To assess feasibility and outcomes of left atrial appendage (LAA) closure when using a patent foramen ovale (PFO) for left atrial access. Background: Because of the fear of entering the left atrium too high, using a PFO for left atrial access during LAA occlusion (LAAO) is generally discouraged. We report our single-center experience using a concomitant PFO for LAAO, thereby avoiding transseptal puncture.

01 febrero 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Optical coherence tomography imaging of the patent ductus arteriosus: First known uses in congenital heart disease

James A. Hill MD*, Guruprasad Mahadevaiah MD andMichael W. Jenkins PhD

Background: Angiography is used to assess ductal morphology and caliber during interventional closure of the ductus arteriosus. We are evaluating the use of optical coherence tomography (OCT) to evaluate ductal anatomy given the potential benefit of superior resolution and lower radiation.

01 febrero 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Left atrial appendage closure using the amulet device: An initial experience with the second generation amplatzer cardiac plug

Simon Cheung Chi Lam MD, Stefan Bertog MD, Sameer Gafoor MD, Laura Vaskelyte MD, Patrick Boehm, Raymond Wei Jian Ho, Jennifer Franke MD, Ilona Hofmann MD andHorst Sievert MD, PhD*

Objectives: Aim of this study was to demonstrate the feasibility, safety, and short-term outcome of left atrial appendage (LAA) closure with a new generation LAA closure device.

01 febrero 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Cardiac CT and echocardiographic evaluation of peri-device flow after percutaneous left atrial appendage closure using the AMPLATZER cardiac plug device

Milosz Jaguszewski MD1,†, Costantina Manes MD1,†, Gilbert Puippe MD2,†, Sacha Salzberg MD3, Maja Müller BSc1, Volkmar Falk MD3, Thomas Lüscher MD1, Andreas Luft MD4, Hatem Alkadhi MD, MPH, EBCR2 andUlf Landmesser MD1,*

Objectives: The aim of the study was to examine frequency, size, and localization of peri-device leaks after percutaneous left atrial appendage (LAA)-closure with the AMPLATZER-Cardiac-Plug (ACP) by using a multimodal imaging approach, i.e. combined cardiac-CT and TEE follow-up.

01 febrero 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Safety and long-term outcomes after percutaneous coronary intervention in patients with human immunodeficiency virus

Salem Badr MD, Sa´ar Minha MD, Hironori Kitabata MD, PhD, Omid Fatemi MD, Rebecca Torguson MPH, Fang Chen, PhD, William O. Suddath MD, Lowell F. Satler MD, Augusto D. Pichard MD andRon Waksman MD*

Objective: This study aims to report the long-term outcomes after percutaneous coronary intervention (PCI) in human immunodeficiency virus (HIV+) patients.

01 febrero 2015

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions

Paul S. Teirstein MD, FACC1,*, Ian T. Meredith MBBS, PHD, FACC2, Robert L. Feldman MD, FACC3, A. Charles Rabinowitz MD, FACC4, Louis A. Cannon MD, FACC5, Tommy C. Lee MD, FACC6, Joseph Dens MD, PHD, FACC7, Christophe L. Dubois MD, PHD8,9, Michael R. Mooney MD, FACC10, Vincent J. Pompili MD, FACC11, Shigeru Saito MD, FACC12, Dominic J. Allocco MD, FACC13, Keith D. Dawkins MD, FACC13 andGregg W. Stone MD, FACC14

Objectives: To report 1- and 2-year clinical outcomes of patients receiving platinum chromium everolimus-eluting stents (PtCr-EES) in the prospective, single-arm PLATINUM small vessel (SV) and long lesion (LL) studies.